Lucrezia De Pascalis

Title: The Innovative Contributions of Lucrezia De Pascalis

Introduction

Lucrezia De Pascalis is a prominent inventor based in Cambridge, Massachusetts. Her dedication to advancing medical science is evident in her innovative work, particularly in the realm of biochemistry. With a focus on genetic mutations, her inventions aim to provide solutions for individuals suffering from specific health conditions.

Latest Patents

De Pascalis holds a patent for "Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations." This groundbreaking invention relates to compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are designed to stabilize a mutant phenylalanine hydroxylase (PAH) protein or reduce blood phenylalanine concentration in patients with phenylketonuria. Notable mutations addressed in her patent include R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, and V388M. The implications of this innovation are significant for the treatment of metabolic disorders.

Career Highlights

De Pascalis is associated with Agios Pharmaceuticals, Inc., a company focused on advancing therapies for genetically-defined diseases. Her work at Agios Pharmaceuticals exemplifies her commitment to addressing critical health challenges through scientific research and innovation.

Collaborations

Throughout her career, Lucrezia De Pascalis has collaborated with talented colleagues, including Heather Jane Finlay and Sandra King. These partnerships have not only enhanced the quality of her work but also contributed to a collaborative atmosphere where innovative ideas can flourish.

Conclusion

The contributions of Lucrezia De Pascalis highlight the importance of innovation in the medical field. Her patent offers hope to those affected by phenylketonuria, symbolizing a step forward in genetic treatment. With ongoing collaboration and dedication, her work is bound to influence future advancements in biochemistry and patient care.